Table 2.

Postvaccination Proportions of Infants Seroprotected Against Measles and Rubella, With Accompanying Between-Group Differences and Geometric Mean Concentrations (GMCs)

Immune Measure	MR + HRV			MR Alone			Difference in Seroconversion
	Subjects, Proportion	% (95% CI)	GMC (95% CI)	Subjects, Proportion	% (95% CI)	GMC (95% CI)	% (95% CI)
Measles virus SNAsa	171/227	75.3 (69.3–80.5)	196.3 (175.3–219.7)	173/233	74.3 (68.3–79.4)	194.2 (174.0–216.7)	1.1 (−6.9 to 9.0)
Anti–measles virus IgGb	219/227	96.5 (93.2–98.2)	Not defined	227/232	97.8 (95.1–99.1)	Not defined	−1.4 (−4.9 to 1.9)
Anti–rubella virus IgGc	228/228	100.0 (98.3–100.0)	191.9 (174.8–210.7)	233/234	99.6 (97.6–99.9)	177.8 (161.8–195.4)	0.4 (−1.3 to 2.4)

Data are for all children meeting inclusion/exclusion criteria.

Abbreviations: CI, confidence interval; HRV, human rotavirus vaccine; IgG, immunoglobulin G; MR, measles-rubella vaccine.

^a Defined as a measles virus serum neutralization antibody (SNA) concentration of >120 mlU/mL.

^b Defined by operating characteristic of the enzyme-linked immunoassay (EIA). Seroprotective levels are not defined for the EIA.

^c Defined as a rubella virus IgG concentration of ≥10 IU/mL.